

COMPANY OVERVIEW

Norovirus is a very common and highly contagious virus that causes symptoms of acute gastroenteritis including nausea, vomiting, stomach pain and diarrhea. Other symptoms include fatigue, fever and dehydration. Noroviruses are a major cause of gastrointestinal illness in closed and crowded environments, having become notorious for their common occurrence in hospitals, nursing homes, childcare facilities and cruise ships. In the United States alone, noroviruses are the most common cause of acute gastroenteritis and are estimated to cause 21 million illnesses each year and contribute to 70,000 hospitalizations and 800 deaths. Noroviruses are responsible for up to 1.1 million hospitalizations and 218,000 deaths annually in children in the developing world. There is currently no effective treatment or effective vaccine for norovirus, and the ability to curtail outbreaks is limited. Few companies, if any, are developing antiviral treatments for this disease. However, three candidate vaccines are currently in early stages of clinical testing by GlaxoSmithKline, Ligocyte and Takeda Pharmaceuticals. By targeting viral replication enzymes, we believe it is possible to develop an effective treatment for all geno-groups of the norovirus. Also, because of the significant unmet medical need and the possibility of chronic norovirus infection in immunocompromised individuals, new antiviral therapeutic approaches may warrant an accelerated path to market.

RECENT NEWS

Cocrystal Pharma Presents Positive Preclinical Data for CC-42344 at the Options X for the Control of Influenza Conference

Sep 3 2019, 8:05 AM EDT

Cocrystal Pharma Announces Abstract Accepted for Oral Presentation at the ISIRV: Options X for the Control of Influenza Conference

Aug 21 2019, 8:05 AM EDT

Cocrystal Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Aug 9 2019, 8:05 AM EDT

STOCK OVERVIEW

Symbol	COCP
Exchange	Nasdaq
Market Cap	57.87m
Last Price	\$1.83
52-Week Range	\$1.51 - \$5.28

09/17/2019 04:00 PM EDT

INVESTOR RELATIONS

Jenene Thomas Communications
Jenene Thomas
T: 833-475-8247
cocp@jtcir.com

MANAGEMENT TEAM

Gary Wilcox, Ph.D.

Chairman of the Board and Chief Executive Officer

Sam Lee, Ph.D.

President

James J. Martin

Chief Financial Officer

COCRYSTAL PHARMA, INC.

19805 N. Creek Parkway
Bothell, WA 98011
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.